Richmond, CA, United States of America

Paul Rennie

USPTO Granted Patents = 16 

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 217(Granted Patents)


Location History:

  • Vancouver, CA (2012)
  • Richmond, CA (2005 - 2020)

Company Filing History:


Years Active: 2005-2020

Loading Chart...
16 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Paul Rennie

Introduction

Paul Rennie is a distinguished inventor based in Richmond, California, known for his significant contributions to the field of therapeutics. With a total of 16 patents to his name, he has made remarkable strides in developing compounds for medical applications, particularly in the treatment of prostate cancer.

Latest Patents

Among his latest innovations is the patent for Binding Function 3 (BF3) site compounds as therapeutics and methods for their use. This invention provides compounds with specific structures that are designed for treating various medical indications, including prostate cancer. The methods of treatment involving these compounds are also outlined, showcasing the potential impact of his work on cancer therapies.

Career Highlights

Throughout his career, Paul Rennie has worked with notable institutions, including the University of British Columbia and Teva Pharmaceutical Industries Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Martin E. Gleave and Colleen Nelson, who have played significant roles in advancing the research and development of therapeutic compounds alongside Rennie.

Conclusion

Paul Rennie's innovative work in the field of therapeutics, particularly in developing treatments for prostate cancer, highlights his importance as an inventor. His contributions continue to influence the medical community and pave the way for future advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…